Progesterone Metabolism in Normal Human Endometrium During the Menstrual Cycle and in Endometrial Carcinoma

Pollow, K.; Lübbert, H.; Boquoi, E; Pollow, Barbara

doi:10.1210/jcem-41-4-729

Cited by 34 publications

(16 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These findings are in agree ment with the data reported by Bayard et al [3] and Pollow et al [4] for human endometrium and endo metrial carcinoma and underline the decisive role which the hormonal milieu plays in relation to receptor in cidence and receptor concentration also in malignant tissues. Although variations of the ER concentrations in dependency on the hormonal milieu could be ex pected for normal target tissues because of the now well-established influence of the hormone concentra tion on receptor biosynthesis [11,12], the discovery of cycle-mediated alterations of receptor incidence and concentration in malignant tissues seems to be some what unexpected.…”

Section: Discussionsupporting

confidence: 92%

“…Similar variations in the receptor concentrations could also be demonstrated by Bayard et al [3], Pollow et al [4] and others for human endometrium and myometrium. In these tissues the highest estradiol receptor (ER) levels were observed in the early proliferative phase of the menstrual cycle, whereas the progesterone receptor concentration show ed its maximum at midcycle.…”

supporting

confidence: 83%

“…The existence or absence of ER in malignant tissues are thought to be in first line an expression of the grade of differentiation or dedifferen tiation of the tissue. The findings described by Henson et al [13] and others for mammary cancers and by Pollow et al [4] for endometrial carcinoma underline the importance of the tissue differentiation for the existence of ER.…”

Section: Discussionmentioning

confidence: 72%

See 2 more Smart Citations

Estradiol Receptor in Human Breast Cancers throughout the Menstrual Cycle

Heise¹,

Görlich²

1982

Oncology

View full text Add to dashboard Cite

The existence and the concentration of the estradiol receptor (ER) in breast cancers of pre- and postmenopausal patients were measured. ER status and concentration are significantly higher in cancers of postmenopausal women. Breast cancers operated at various phases of the menstrual cycle showed remarkable differences in ER incidence and concentration. The highest values were found in the early proliferative phase, whereas the ER incidence is lowest in cancers which were operated at early secretory phase. ER concentrations found in late proliferative and late secretory phases are significantly lower than those found in cancers of postmenopausal patients. Statistically significant differences of the ER concentrations between the various phases of the menstrual cycle could not be secured.

show abstract

Section: Discussionsupporting

confidence: 92%

supporting

confidence: 83%

Section: Discussionmentioning

confidence: 72%

See 1 more Smart Citation

Estradiol Receptor in Human Breast Cancers throughout the Menstrual Cycle

Heise¹,

Görlich²

1982

Oncology

View full text Add to dashboard Cite

show abstract

“…The P receptor concentration in human endometrium varies systematically during the menstrual cycle with maximum levels at midcycle (22). This observation has been interpreted to indicate that the endometrial P receptor is estrogen dependent.…”

Section: Methodsmentioning

confidence: 97%

Endocrine Consequences of Continuous Antiestrogen Therapy with Tamoxifen in Premenopausal Women

Sherman¹,

Chapler²,

Crickard³

et al. 1979

J. Clin. Invest.

147

View full text Add to dashboard Cite

A B S T R A C T Daily administration of estrogen antagonists to premenopausal women has been incorporated into the adjuvant treatment ofbreast cancer. We have studied the changes in reproductive hormones, pituitary responses to hypothalamic-releasing hormones, and endometrial histology during treatment with the antiestrogen tamoxifen in five healthy, premenopausal women. These studies were carried out during one menstrual cycle before and during two cycles ofantiestrogen treatment. All subjects continued to have regular menses with biphasic basal body temperature records. During treatment, estradiol (E2) levels were increased but followed the usual pattern reflecting follicular maturation and corpus luteum formation. The mean E2 concentration at the midcycle peak and during the luteal phase was twice that observed during the non-treatment cycle. By contrast, the concentrations and secretory patterns of luteinizing hormone and follicle-stimulating hormone were not greatly changed, and the gonadotropin responses to gonadotropin-releasing hormone were not suppressed.Endometrial biopsies obtained during the follicular phase of control and tamoxifen treatment cycles showed no differences whereas biopsies obtained during the luteal phase of tamoxifen cycles uniformly showed a lack of changes attributed to progesterone action with no progression of histologic changes beyond those expected on day 7-8 of the luteal phase.These observations are consistent with maturation of multiple ovarian follicles, a surprising finding considering the normal gonadotropin concentrations. The retarded development of the endometrium in the presence of supranormal serum E2 and progesterone concentrations is a morphologic demonstration of the antiprogestational effect of antiestrogens. The lack of gonadotropin suppression in the presence of hyper-

show abstract

“…Locally P can be converted to the less active 20α-hydroxyprogesterone (20α-OHP) and/or to 5α-reduced metabolites (Pollow et al, 1975). The major human reductive 20α-HSDs are aldo-keto reductases AKR1C1 and AKR1C3, with the latter also acting as a reductive 17β-HSD and potentially also involved in E2 synthesis (Penning 2000).…”

Section: Page 3 Of 14mentioning

confidence: 99%

Disturbed estrogen and progesterone action in ovarian endometriosis

Šmuc

Hevir

Ribič-Pucelj

et al. 2009

Molecular and Cellular Endocrinology

View full text Add to dashboard Cite

Please cite this article as:Šmuc, T., Hevir, N., Ribič-Pucelj, M., Husen, B., Thole, H., Rižner, T.L., Disturbed estrogen and progesterone action in ovarian endometriosis, Molecular and Cellular Endocrinology (2007), doi:10.1016/j.mce.2008 This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. SummaryEndometriosis is a very common disease in pre-menopausal women, where defective metabolism of steroid hormones plays an important role in its development and promotion. In the present study, we have examined the expression of 11 estrogen and progesterone metabolizing enzymes and their corresponding receptors in samples of ovarian endometriomas and control endometrium. Expression analysis revealed significant up-regulation of enzymes involved in estradiol formation (aromatase, sulfatase and all reductive 17β-hydroxysteroid dehydrogenases) and in progesterone inactivation (AKR1C1 and AKR1C3). Among the estrogen and progesterone receptors, ERα was down-regulated, ERβ was up-regulated, and there was no significant difference in expression of progesterone receptors A and B (PRAB). Our data indicate that several enzymes of estrogen and progesterone metabolism are aberrantly expressed in endometriosis, which can lead to increased local levels of mitogenic estradiol and decreased levels of protective progesterone. Changes in estrogen receptor expression suggest that estradiol may also act via non-estrogen-receptor-mediated pathways, while expression of progesterone receptors still needs further investigation.

show abstract

Progesterone Metabolism in Normal Human Endometrium During the Menstrual Cycle and in Endometrial Carcinoma

Cited by 34 publications

References 14 publications

Estradiol Receptor in Human Breast Cancers throughout the Menstrual Cycle

Estradiol Receptor in Human Breast Cancers throughout the Menstrual Cycle

Endocrine Consequences of Continuous Antiestrogen Therapy with Tamoxifen in Premenopausal Women

Disturbed estrogen and progesterone action in ovarian endometriosis

Contact Info

Product

Resources

About